静脉克拉霉素对脓毒症、呼吸及多器官功能障碍综合征患者的影响:一项随机临床试验
这项多中心随机临床试验纳入氧合指数(PaO2/FiO2)低于200且非呼吸系统SOFA评分超过3分的脓毒症患者,随机接受克拉霉素1克静脉注射每日一次连续4天或安慰剂。28天全因死亡率克拉霉素组49.1% vs 安慰剂组45.5%(风险差3.6%,95%CI -15.7至22.7;P=0.703),无统计学差异;90天死亡率和脓毒症反应也无差异。克拉霉素与更低的脓毒症复发率相关(OR 0.21,95%CI 0.06-0.68;P=0.012),并伴随单核细胞HLA-DR表达增加、非经典单核细胞扩增及胆固醇稳态相关基因上调。结论认为克拉霉素未降低该类患者死亡率,但可能通过免疫恢复机制减少复发。
要点
- 纳入标准:脓毒症患者,PaO2/FiO2<200且非呼吸系统SOFA评分>3分。
- 干预:克拉霉素1克静脉注射每日一次连续4天,对照为安慰剂。
- 主要终点:28天全因死亡率克拉霉素组49.1% vs 安慰剂组45.5%(风险差3.6%,95%CI -15.7至22.7;P=0.703,调整OR 1.03,95%CI 0.35-3.06;P=0.959)。
- 次要终点:克拉霉素组脓毒症复发率更低(OR 0.21,95%CI 0.06-0.68;P=0.012);90天死亡率和脓毒症反应无统计学差异。
- 安全性:严重和非严重不良事件在两组间分布均等。
适用人群与场景
- 脓毒症患者,氧合指数(PaO2/FiO2)<200且非呼吸系统SOFA评分>3分。
- 研究在多个中心进行,纳入时间为2017年12月至2019年9月。
诊断标准与关键阈值
- 脓毒症诊断基础上,PaO2/FiO2<200。
- 非呼吸系统SOFA评分>3分。
处置流程与药物剂量
- 克拉霉素1克静脉注射,每日一次,连续4天。
- 对照组使用安慰剂。
研究设计与关键结果
- 多中心随机临床试验,每组55例患者。
- 28天全因死亡率:克拉霉素组27例(49.1%)vs 安慰剂组25例(45.5%),风险差3.6%(95%CI -15.7至22.7;P=0.703),调整OR 1.03(95%CI 0.35-3.06;P=0.959)。
- 90天死亡率和脓毒症反应(第7天SOFA评分至少下降25%)无统计学差异。
- 脓毒症复发:克拉霉素组与安慰剂组相比OR 0.21(95%CI 0.06-0.68;P=0.012)。
- 克拉霉素组单核细胞HLA-DR表达显著增加,非经典单核细胞扩增,胆固醇稳态相关基因上调。
- 严重和非严重不良事件在两组间分布均等。
证据类型、等级与局限
- 证据类型:多中心随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为克拉霉素未降低脓毒症合并呼吸及多器官功能障碍患者的死亡率,但可能通过免疫恢复机制降低脓毒症复发。
指南或共识出处
- 临床试验注册:ClinicalTrials.gov标识符NCT03345992,注册日期2017年11月17日;EudraCT 2017-001056-55。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Clarithromycin may act as immune-regulating treatment in sepsis and acute respiratory dysfunction syndrome. However, clinical evidence remains inconclusive. We aimed to evaluate whether clarithromycin improves 28-day mortality among patients with sepsis, respiratory and multiple organ dysfunction syndrome.
METHODS: We conducted a multicenter, randomized, clinical trial in patients with sepsis. Participants with ratio of partial oxygen pressure to fraction of inspired oxygen less than 200 and more than 3 SOFA points from systems other than the respiratory function were enrolled between December 2017 and September 2019. Patients were randomized to receive 1 gr of clarithromycin or placebo intravenously once daily for 4 consecutive days. The primary endpoint was 28-day all-cause mortality. Secondary outcomes were 90-day mortality; sepsis response (defined as at least 25% decrease in SOFA score by day 7); sepsis recurrence; and differences in peripheral blood cell populations and leukocyte transcriptomics.
RESULTS: Fifty-five patients were allocated to each arm. By day 28, 27 (49.1%) patients in the clarithromycin and 25 (45.5%) in the placebo group died (risk difference 3.6% [95% confidence interval (CI) - 15.7 to 22.7]; P = 0.703, adjusted OR 1.03 [95%CI 0.35-3.06]; P = 0.959). There were no statistical differences in 90-day mortality and sepsis response. Clarithromycin was associated with lower incidence of sepsis recurrence (OR 0.21 [95%CI 0.06-0.68]; P = 0.012); significant increase in monocyte HLA-DR expression; expansion of non-classical monocytes; and upregulation of genes involved in cholesterol homeostasis. Serious and non-serious adverse events were equally distributed.
CONCLUSIONS: Clarithromycin did not reduce mortality among patients with sepsis with respiratory and multiple organ dysfunction. Clarithromycin was associated with lower sepsis recurrence, possibly through a mechanism of immune restoration. Clinical trial registration clinicaltrials.gov identifier NCT03345992 registered 17 November 2017; EudraCT 2017-001056-55.
参考来源
- Karakike E, Scicluna BP, Roumpoutsou M, et al. Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial. Crit Care. 2022. PMID: 35717241. doi:10.1186/s13054-022-04055-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。